WallStSmart

Johnson & Johnson (JNJ)vsStandard Biotools Inc (LAB)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Johnson & Johnson generates 117554% more annual revenue ($99.33B vs $84.43M). LAB leads profitability with a 157.6% profit margin vs 16.2%. JNJ earns a higher WallStSmart Score of 54/100 (C-).

JNJ

Buy

54

out of 100

Grade: C-

Growth: 4.7Profit: 8.5Value: 3.7Quality: 5.5
Piotroski: 3/9Altman Z: 2.64

LAB

Hold

42

out of 100

Grade: D

Growth: 2.7Profit: 4.0Value: 6.7Quality: 7.0
Piotroski: 4/9Altman Z: -1.01
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for JNJ.

LABUndervalued (+89.2%)

Margin of Safety

+89.2%

Fair Value

$11.06

Current Price

$0.65

$10.41 discount

UndervaluedFair: $11.06Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

JNJ3 strengths · Avg: 8.7/10
Market CapQuality
$657.68B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
25.7%8/10

Strong operational efficiency at 25.7%

Free Cash FlowQuality
$6.36B8/10

Generating 6.4B in free cash flow

LAB3 strengths · Avg: 10.0/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Profit MarginProfitability
157.6%10/10

Keeps 158 of every $100 in revenue as profit

Debt/EquityHealth
0.0510/10

Conservative balance sheet, low leverage

Areas to Watch

JNJ4 concerns · Avg: 2.8/10
Price/BookValuation
8.4x4/10

Trading at 8.4x book value

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.072/10

Expensive relative to growth rate

P/E RatioValuation
41.5x2/10

Premium valuation, high expectations priced in

LAB4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$243.19M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-16.8%2/10

ROE of -16.8% — below average capital efficiency

Revenue GrowthGrowth
-0.9%2/10

Revenue declined 0.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : JNJ

The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.7%.

Bull Case : LAB

The strongest argument for LAB centers on Price/Book, Profit Margin, Debt/Equity. Profitability is solid with margins at 157.6% and operating margin at -41.7%.

Bear Case : JNJ

The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 41.5x leaves little room for execution misses.

Bear Case : LAB

The primary concerns for LAB are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

JNJ profiles as a mature stock while LAB is a declining play — different risk/reward profiles.

LAB carries more volatility with a beta of 1.51 — expect wider price swings.

JNJ is growing revenue faster at 5.9% — sustainability is the question.

JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.

Bottom Line

JNJ scores higher overall (54/100 vs 42/100), backed by strong 16.2% margins. LAB offers better value entry with a 89.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Johnson & Johnson

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Visit Website →

Standard Biotools Inc

HEALTHCARE · MEDICAL DEVICES · USA

Standard Biotools Inc. (LAB) is a pioneering biotechnology company dedicated to enhancing genomic analysis and biological research through cutting-edge tools and technologies. The firm's focus on developing high-performance products for laboratories in genomics and proteomics is aimed at improving research precision and operational efficiency. Utilizing proprietary platforms, Standard Biotools accelerates scientific discoveries, reinforcing its position as a leader in the dynamic biotechnology landscape. With a commitment to meeting the growing demand for innovative analytical solutions, LAB is strategically positioned to facilitate significant advancements within the life sciences sector.

Want to dig deeper into these stocks?